ArticleInfection and drug resistance2020
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Frequency and antimicrobial resistance pattern of non lactose fermenting gram negative rods in neurosurgical patients outlining aminoglycoside resistance genes.BMC microbiology · 2025Article
- Genetic profiling of multidrug-resistantMicrobiology spectrum · 2025Article
- Risk and Prognostic Factors for Bloodstream Infections Due to Clonally TransmittedInfection and drug resistance · 2025Article
- Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance.Frontiers in microbiology · 2024Review
- Carbapenem-ResistantTransboundary and emerging diseases · 2024Article
- Insights into the Intersection of Biocide Resistance, Efflux Pumps, and Sequence Types in Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Carbapenemase genes distribution in clonal lineages ofFrontiers in cellular and infection microbiology · 2023Article
- Constitutive Phenotypic Modification of Lipid A in Clinical Acinetobacter baumannii Isolates.Microbiology spectrum · 2022Article
- Rectal and Tracheal Carriage of Carbapenemase Genes and Class 1 and 2 Integrons in Patients in Neurosurgery Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2022Article
- Effect of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics.Infectious diseases and therapy · 2021Review
- The First Saudi Study Investigating the Plasmid-borne Aminoglycoside and Sulfonamide Resistance amongInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aminoglycosides are widely used for the therapeutic management of infections caused by gram-negative bacteria, including the PURPOSE: This study aimed to investigate the presence of 16SrRNA methylases and aminoglycoside modifying enzymes (AMEs) genes among aminoglycoside resistant MATERIAL AND
methodsThe 143
resultsThe 133/143 (93%) isolates were non-susceptible to at least one of the tested aminoglycosides, including amikacin, gentamicin, and tobramycin. The MIC distribution has shown that 87.486.7% strains were resistant to amikacin and gentamicin, respectively. The DISCUSSION: The study has reported the incidence of various enzymes conferring aminoglycoside resistance among the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.